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Abstract
Purpose The subcutaneous (SC) administration of trastuzumab is highly preferred by patients. At home, administration of 
trastuzumab SC might further improve patient benefit. The aims of the BELIS study are to evaluate the safety and tolerability 
of trastuzumab SC when administered at home by a healthcare professional (HCP) and to evaluate patient-reported outcomes 
for treatment experience of at home cancer therapy.
Methods This open-label phase IIIb study enrolled HER2-positive early breast cancer patients in Belgium and Israel who 
completed the first six cycles of trastuzumab IV (neo)adjuvant therapy. The study consisted of three consecutive treatment 
periods: three cycles of trastuzumab IV and SC each at the hospital and six cycles of trastuzumab SC at home.
Results Between November 2013 and December 2014, 23 centres enrolled 102 patients in the intent-to-treat population of 
which 101 patients entered the safety population. No new safety signals were detected with as expected, more mild admin-
istration site events with trastuzumab SC when compared to IV treatment. All patients agreed that they had benefit from 
at home administration to a large (18/81; 22%) or very large (63/81; 78%) extent. All HCPs (21/21) agreed that SC is the 
quickest method from start of preparation to finish of administration and that less resource use is needed.
Conclusion The results of the BELIS study support that trastuzumab SC can be safely administered at home by a HCP and 
all patients considered this setting as beneficial. HCPs consider the SC formulation as the quickest method to administer 
trastuzumab.
Trial registration EudraCT Identifier: 2013-000123-13. ClinicalTrials.gov Identifier: NCT01926886.
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Introduction
Among females worldwide, breast cancer (BC) is the most 
commonly diagnosed cancer (24% of the total new can-
cer cases) and the leading cause of cancer death (15% of 
the total cancer deaths) [1]. The large majority of newly 
diagnosed BCs are early BC (eBC) and 15% to 20% of 
patients have tumours that exhibit overexpression of the 
Human Epidermal Growth Factor Receptor 2 (HER2) [2, 
3]. These tumours are associated with poorer prognosis 
compared with tumours that do not overexpress HER2 
[4, 5].
It has been demonstrated in large randomized trials that 
adjuvant trastuzumab for HER2-positive eBC improves 
disease-free survival (DFS) and overall survival [6–8]. 
One year adjuvant treatment with trastuzumab is well 
established in HER2-positive eBC. The subcutaneous 
(SC) administration of trastuzumab over about 5 min 
has a pharmacokinetic profile and efficacy non-inferior 
to intravenous (IV) administration with a similar safety 
profile [9–12]. The SC administration of trastuzumab is 
highly preferred by the patients and this is important for 
treatments over prolonged periods of time [13, 14]. At 
home administration of trastuzumab SC might further 
improve the patient satisfaction during treatment com-
pared to administration in the hospital.
An important reduction of patient chair time and active 
healthcare professional (HCP) time with trastuzumab SC 
was demonstrated in the time and motion study within 
the PrefHer study [15]. Shorter patient chair time could 
increase centre capacity and reduce waiting lists. HCP 
time savings could allow for more time dedicated to other 
patient care activities.
The BELIS study is to our knowledge the first prospec-
tive study to assess the overall safety and tolerability of 
trastuzumab SC when administered by a HCP at the home 
of the patient. Patient-reported outcomes for experience 
and satisfaction with the treatment provided at home and 
in the hospital are important aspects of the study.
Methods
Study design, participants and procedures
For this prospective, phase IIIb, open-label, multinational, 
multicentre study, centres in Belgium and Israel enrolled 
patients with HER2-positive eBC. Eligible patients with an 
Eastern Cooperative Oncology Group (ECOG) performance 
status of 0–1, a left ventricular ejection fraction (LVEF) of 
at least 50%, had completed the first six cycles of (neo)adju-
vant trastuzumab treatment were enrolled in the intent-to-
treat population (ITT). All enrolled patients who received at 
least one dose of the study medication (trastuzumab SC or 
trastuzumab IV) were included in the safety (SA) popula-
tion. Patients were treated with surgery, chemotherapy, radi-
otherapy or hormonotherapy according to local standards. 
The study included three consecutive trastuzumab treatment 
periods. In the first treatment period, patients received in the 
hospital three cycles of the recommended maintenance dose 
of 6 mg/kg trastuzumab IV at 3-weekly intervals. In the sec-
ond treatment period, patients received in the hospital three 
cycles of trastuzumab SC 600 mg fixed dose at 3-weekly 
intervals. In the third treatment period, patients received 
at home six cycles of 600 mg trastuzumab SC fixed dose, 
administered by a trained HCP at 3-weekly intervals (Fig. 1).
The safety follow-up visit, 4 weeks after the end of treat-
ment, was followed by a long-term follow-up period of two 
years with four visits every 6 months.
Outcomes
Primary outcome of the study was overall safety and toler-
ability of trastuzumab SC when administered at home by a 
trained HCP. The adverse events (AE) and serious adverse 
events (SAE) were continuously monitored and documented 
during the entire study, at each 3-weekly treatment visit and 
during post-treatment follow-up. Intensity of the recorded 
AEs were graded according to the National Cancer Institute 
Common Terminology Criteria for Adverse Events (NCI 
CTCAE) version 4.0. Adverse events of special interest, such 
as congestive heart failure (CHF), LVEF decrease over time 
Fig. 1  Study design
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or other cardiac events were collected. Secondary objec-
tives were patient experience with trastuzumab IV and SC, 
patient-reported quality of care, patient-reported symptoms, 
HCP overall satisfaction and perceived time savings and effi-
cacy assessed through disease-free survival (DFS).
In order to evaluate the patient experience with tras-
tuzumab IV and SC administered in the hospital, HCPs 
interviewed the patients before the start of the third dose of 
trastuzumab at the hospital and completed the patient expe-
rience (PEX)-P1questionnaire which contains 25 items. At 
the safety follow-up visit, patients were interviewed again 
by the HCP to complete the 6-item PEX-P2 questionnaire 
to evaluate their experience with trastuzumab SC adminis-
tered at home. To evaluate overall perception of the qual-
ity of care in the hospital, patients completed the patient 
satisfaction (PS)Q1 questionnaire before receiving the first 
dose of trastuzumab SC at home. PSQ1 is a quality of care 
questionnaire containing 28 questions categorised on the 
opinion of patients about the clinicians, the hospital staff 
and other questions. To evaluate the experience with at home 
treatment, patients completed the PSQ2 questionnaire before 
receiving the fifth cycle of trastuzumab SC at home. PSQ2 
is a quality of care questionnaire similar to PSQ1 contain-
ing 26 questions. Also patients rated interference with daily 
life and the severity of 13 symptoms (pain, fatigue, nau-
sea, vomiting, disturbed sleep, distress, shortness of breath, 
memory difficulties, lack of appetite, drowsiness, dry mouth, 
sadness, numbness or tingling) on a ten-point scale of the 
MD Anderson Symptom Inventory (MDASI) questionnaire 
at cycles 7, 10, 13 and 16. Health care professionals com-
pleted the Healthcare Professionals’ Experience (HCPEX) 
questionnaire to evaluate overall satisfaction and perceived 
time savings with trastuzumab SC, after at least 3 patients 
had completed the hospital SC and IV treatment periods.
Disease-free survival, defined as time from the date of 
first study drug administration to the date of local, regional 
or distant recurrence, contralateral BC or death due to any 
cause was monitored. Diagnosis of BC relapse was made 
based on routine clinical practice.
Statistical methods
Descriptive statistical methods were used to analyse and 
report the results of this single-arm study. It was planned 
to enrol 100 patients. This sample size was not based on 
a formal calculation but mainly driven by feasibility and 
a reasonable width of a 95% confidence interval (CI) for 
the rate of AEs and SAEs. Based on an expected rate of 
AEs of 97% [9] and 100 patients, a 95% CI of 91% to 99% 
would be obtained. For an expected rate of SAEs of 21% 
[9] and 100 patients, a 95% CI ranging from 13 to 29% 
would be obtained (CIs calculated using Clopper–Pearson 
methodology).
The protocol with a full description of the methods and 
the questionnaires used, is available in Online Resource 1.
Results
Between November 2013 and December 2014, 23 centres, 
13 in Belgium and 10 in Israel, screened 105 patients and 
enrolled 102 patients in the intent-to-treat (ITT) population, 
51 patients in Belgium and 51 patients in Israel. One ITT 
patient did not receive trastuzumab and was excluded from 
the safety (SA) population. Twenty patients did not complete 
the study period. The most important reason was withdrawal 
of consent during the hospital IV and SC treatment periods 
(Fig. 2).
In the SA population, overall mean age at screening was 
54 years (range 24–80 years). All patients were female 
except for one male patient. Medical and breast cancer 
disease history were recorded: 73.3% of patients in the SA 
population had an oestrogen receptor positive tumour and 
50.5% of patients a progesterone receptor positive tumour 
(Table 1).
Safety results during the treatment period 
and 4 weeks safety follow‑up
A total of 551 AEs were reported in 91/101 (90.1%–95% 
CI [82.54–95.15]) patients. Of these, 194 events in 52/101 
(51.5%–95% CI [41.33–61.55]) patients were considered 
to be related to trastuzumab. During the 3 cycles of trastu-
zumab IV at the hospital, 7/101 (6.9%–95% CI [2.83–13.76]) 
patients experienced a total of 7 trastuzumab-related AEs. 
During the 3 cycles of trastuzumab SC at the hospital, 
30/94 (31.9%–95% CI [22.67–42.33]) patients experi-
enced a total of 49 trastuzumab-related AEs. During the 6 
cycles with trastuzumab SC at home, 40/86 (46.5%–95% 
CI [35.68–57.59]) patients experienced a total of 139 tras-
tuzumab-related AEs. It is to be noted that the number of 
cycles during the at home SC treatment is twofold higher (6 
cycles) compared to the number of cycles during the hospi-
tal IV or SC treatment periods (3 cycles). The related AEs 
observed in at least 5% of the patients during at least 1 treat-
ment period were mostly administration site conditions and 
fatigue with trastuzumab SC (Table 2). Most of the related 
and unrelated AEs were graded CTC 1 or 2 (Table 3). Data 
of the administrations site conditions and fatigue at patient 
level are available in Online Resource 2. 
Overall, four cardiac AEs were reported in four patients 
(atrial fibrillation, sinus tachycardia, hypertension and 
palpitation).
A total of eight SAEs were reported in eight patients. Of 
these, five were considered to be related to trastuzumab, all 
five were a decrease of LVEF. Two cases of LVEF decrease 
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during the hospital treatment period led to withdrawal of 
the study treatment. Two cases of LVEF decrease occurred 
in the at home treatment period. During the at home treat-
ment period, there were no AEs that led to discontinuation 
of study medication.
Safety results during the long‑term follow‑up
During the long-term safety follow-up period, a total 
of 35 non-emergent AEs were reported in 24 patients. 
Non-emergent AEs are defined as events occurring at least 
35 days after the last study drug administration. Three 
cardiac non-emergent AEs were reported in 3 patients dur-
ing the long-term follow-up. One decrease in LVEF was 
a serious cardiac non-emergent AE considered related to 
trastuzumab. Left ventricular dysfunction and atrial tachy-
cardia were non-serious non-emergent cardiac events. Two 
deaths were reported, both assessed unrelated to trastu-
zumab. There were no reports of CHF events during the 
entire conduct of the study.
Fig. 2  Patient disposition
101Breast Cancer Research and Treatment (2020) 181:97–105 
1 3
The patient experience questionnaires PEX‑P1, 
PEX‑P2 and MDASI
HCPs interviewed the patients about their experience with 
IV and SC trastuzumab administration in the hospital and 
trastuzumab SC administration at home. Travelling to the 
hospital for treatment was a problem for 18/87 (20.7%) of 
patients (Belgium 6.3%–Israel 38.5%), mainly due to long 
travelling time, unable to travel alone, cost and difficulties 
to travel. The SC injection took 10 min or less for almost all 
patients. The complete treatment session was reduced to 2 h 
for all at home treated patients 82/82 (100%), the majority 
71/82 (86.6%) of patients was not at all anxious during the 
at home treatment and 79/82 (96.3%) patients indicated that 
the treatment session at home was acceptable (Fig. 3).
Results of the patient satisfaction questionnaires PSQ1 
and PSQ2, completed by the patients, indicated that patients 
had confidence and felt supported by the doctors and nurses 
in the hospital and in the at home setting. Overall, patients 
were satisfied to a large or very large extent with the help 
and treatment they received in the hospital 83/84 (98.8%) 
and at home 81/81 (100%). However, 24/82 (29.3%) patients 
indicated that they had to wait quite long or very long before 
being admitted for service at the institution (Table 4). All 
patients 81/81 (100%) indicated that home care was ben-
eficial to a large 18/81 (22.2%) or very large 63/81 (77.8%) 
extent and this benefit was very important or of utmost 
importance for 62/82 (75.6%) patients.
On the MDASI scale, all experienced symptoms were 
rated as relatively mild with all mean scores remaining lower 
than or equal to 3.76 on the 10-point scale at all time points. 
Most severe symptoms were fatigue, disturbed sleep and 
numbness or tingling. The interference of those symptoms 
with the daily life and functioning also remained equal or 
lower to the mean score of 3.34 on the 10-point scale at all 
time points.
Table 1  Population characteristics








History of breast cancer (primary tumour)
Primary tumour size, n (%)
 < 2 cm 47 (46.5%)
 2 cm–5 cm 43 (42.6%)
 > 5 cm 11 (10.9%)
Breast cancer  subtypea, n (%)
 Ductal 90 (89.1%)
 Lobular 3 (3.0%)
 Both ductal and other 4 (4.0%)
 Other 4 (4.0%)
Breast cancer type, n (%)
 Operable 93 (92.1%)
 Locally advanced inoperable 6 (5.9%)
 Inflammatory 2 (2.0%)
Nuclear grade, n (%)
 Grade 1 1 (1.0%)
 Grade 2 34 (33.7%)
 Grade 3 46 (45.5%)
 Unknown/missing 20 (19.8%)
Oestrogen receptor positive, n (%) 74 (73.3%)
Progesterone receptor positive, n (%) 51 (50.5%)
Primary surgery for breast cancer
Lymph node status, n (%)
 Node negative 59 (58.4%)
 Node positive 40 (39.6%)
 Unknown/missing 2 (2.0%)
Table 2  Patients with AEs related to study drug occurring in at least 5% of patients during at least 1 treatment period
Trastuzumab-related adverse events Trastuzumab IV 











Any AE related to study drug, n (%) 7 (6.9%) 30 (31.9%) 40 (46.5%)
General disorders and administration site conditions, n (%) 2 (2.0%) 20 (21.3%) 33 (38.4%)
 Injection site swelling, n (%) 0 (0%) 2 (2.1%) 13 (15.1%)
 Injection site pain, n (%) 0 (0%) 8 (8.5%) 7 (8.1%)
 Injection site erythema, n (%) 0 (0%) 4 (4.3%) 12 (14.0%)
 Fatigue, n (%) 1 (1.0%) 3 (3.2%) 5 (5.8%)
Musculoskeletal and connective tissue disorders, n (%) 0 (0%) 8 (8.5%) 5 (5.8%)
 Myalgia, n (%) 0 (0%) 4 (4.3%) 2 (2.3%)
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Table 3  Patients with AEs by worst intensity









SC at home 
6 cycles
N = 86
At least one AE, n (%) 57 (56.4%) 57 (60.6%) 73 (84.9%)
 Grade unknown 1 (1.0%) 0 1 (1.2%)
 CTC grade 1 45 (44.6%) 46 (48.9%) 66 (76.7%)
 CTC grade 2 23 (22.8%) 20 (21.3%) 35 (40.7%)
 CTC grade 3 1 (1.0%) 4 (4.3%) 5 (5.8%)
 CTC grade 4 1(1.0%) 0 0
 CTC grade 5 0 0 0
Injection site swelling, n (%)
 Grade unknown 0 0 0
 CTC grade 1 0 2 (2.1%) 12 (14%)
 CTC grade 2 0 0 1 (1.2%)
 CTC grade 3 0 0 0
 CTC grade 4 0 0 0
Injection site pain, n (%)
 CTC grade unknown 0 0 0
 CTC grade 1 0 6 (6.4%) 6 (7.0%)
 CTC grade 2 0 2 (2.1%) 2 (2.3%)
 CTC grade 3 0 1 (1.1%) 0
 CTC grade 4 0 0 0
Injection site erythema, n (%)
 CTC grade unknown 0 0 0
 CTC grade 1 0 5 (5.3%) 12 (14.0%)
 CTC grade 2 0 0 0
 CTC grade 3 0 0 0
 CTC grade 4 0 0 0
Fatigue, n (%)
 CTC grade unknown 0 0 0
 CTC grade 1 7 (6.9%) 5 (5.3%) 13 (15.1%)
 CTC grade 2 3 (3.0%) 0 9 (10.5%)
 CTC grade 3 0 1 (1.1%) 0
 CTC grade 4 0 0 0
Myalgia, n (%)
 CTC grade unknown 0 0 0
 CTC grade 1 0 3 (3.2%) 3 (3.5%))
 CTC grade 2 1 (1.0%) 1 (1.1%) 1 (1.2%)
 CTC grade 3 0 0 0
 CTC grade 4 0 0 0
Ejection fraction decrease, n (%)
 CTC grade unknown 0 0 0
 CTC grade 1 0 0 0
 CTC grade 2 1 (1.0%) 1 (1.1%) 0
 CTC grade 3 0 1 (1.1%) 2 (2.3%)
 CTC grade 4 0 0 0 Fig. 3  Treatment experience with trastuzumab at the hospital (IV and SC) and at home (SC)
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HCP experience with trastuzumab IV and SC
Results of the HCPEX questionnaire for trastuzumab treat-
ment showed that all HCPs found it very easy or fairly easy 
to administer trastuzumab via the IV or the SC route. How-
ever, 11/21 (52.4%) of responding HCPs estimated that the 
duration of the trastuzumab IV session lasted more than 
2 h but less than 3 h and 5/21 (23.8%) of responding HCPs 
longer than 3 h. All HCPs (21/21; 100%) agreed that SC 
would be the quickest method from start of preparation to 
finish of administration and that less resource use for prepa-
ration and administration was needed.
Efficacy results
Up until the safety follow-up visit (4 weeks after end of treat-
ment), 3 patients had a recurrence of the disease and during 
the 2-year long-term follow-up 9 patients had a recurrence of 
the disease. The median time to event could not be estimated 
because only 12 patients out of 101 (11.9%) had a recurrence 
or progression or died.
Discussion
The BELIS study is the first prospective study to assess 
safety and tolerability of trastuzumab SC administered at 
the home of the patient by a HCP. During the 6 cycles of 
trastuzumab SC at home, 40/86 (46.5%) patients experienced 
a total of 139 trastuzumab-related AEs. As expected, most 
of these related events were mild administration site condi-
tions such as injection site swelling, injection site pain or 
injection site erythema and fatigue. During the 3 cycles of 
trastuzumab IV at the hospital, 7/101 (6.9%) patients expe-
rienced a related AE. No administration site conditions were 
reported during the IV treatment period. During the 3 cycles 
of trastuzumab SC at the hospital the observed AEs were 
again mostly mild grade 1 administration site conditions. 
There was a larger proportion of patients experiencing tras-
tuzumab-related events during the at home treatment period 
compared to the hospital treatment periods. It should be 
noted that the at home period contained 6 treatment cycles 
compared to 3 treatment cycles during the hospital IV and 
SC periods. Also, at home the HCP was responsible for only 
one patient. This might have resulted in a more complete 
reporting of the mostly mild events in the at home setting 
compared to reporting in a busy hospital setting.
During the treatment period, five trastuzumab-related 
SAEs were reported: five cases of LVEF decrease of which 
two during the at home treatment period. During the long-
term safety follow-up, one case of LVEF decrease, classified 
as a SAE related to trastuzumab, was reported. There were 
no cases of CHF during the entire study period. During the 
conduct of the BELIS study, no new safety signals were 
detected for trastuzumab SC. The observed safety profile of 
trastuzumab SC at home and in the hospital was compara-
ble to the safety results of two randomized studies and the 
single-arm study SafeHer [9–12, 16].
Observed differences in AE rates between trastuzumab 
SC and trastuzumab IV in the large PrefHer study were 
driven by injection site reactions. Adverse events rates were 
similar between trastuzumab SC (275/479 [57.4%]) and tras-
tuzumab IV (58/478 [54.0%]) when injection site reactions 
were excluded [10].
An important aspect of the study was the experience and 
satisfaction of the patients with trastuzumab SC treatment 
at the home of the patient. There is an increasing interest in 
the administration of cancer treatment outside the hospital 
based on patient preferences, capacity issues in oncology 
day care hospitals facing an increasing number of patients 
and treatments, and the increased use of oral chemotherapy 
[17]. In a feasibility study of home-based chemotherapy, 
patient benefits of home care included increased comfort 
and freedom [18]. All the patients in the BELIS study who 
completed the questionnaire concerning the quality of care 
in the hospital and at home indicated that being treated at 
home with trastuzumab SC was beneficial to a large or very 
large extent. The duration of the complete treatment session 
was reduced to 2 h for all at home treated patients and dif-
ficulties to travel to the hospital can be avoided. We observed 
surprisingly long treatment sessions in the hospital for the 
trastuzumab SC treatment as well as for the trastuzumab IV 
sessions. The underlying reasons for these long treatment 
sessions are not clear but possibly due to logistic problems 
in the organisation of the hospital.
Results of the BELIS study confirm the benefit for 
patients and HCPs of SC administration of trastuzumab 
compared to IV administration observed in previous studies 
[13, 14, 19]. Also, the time savings observed with SC treat-
ment could lead to a capacity gain of the day care facilities 
and patients spending less time at the hospital, which may 
improve their quality of life. The time and motion study 
within the PrefHer study showed that across different coun-
tries and centres, the trastuzumab SC administration led to 
Table 4  Waiting time before being admitted for service in the hospi-
tal
Did you have to wait long before you were admitted for 
service in the hospital
N = 82
No n (%) 24 (29.3%)
Yes but not long n (%) 34 (41.5%)
Yes quite long n (%) 20 (24.4%)
Yes very long n (%) 4 (4.9%)
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an important reduction of patient chair time and of active 
HCP time [15]. In a single-centre, Belgian, time, motion 
and cost assessment study, it was observed that the total time 
patients spent in the day care centre was 71% shorter with 
SC administration of trastuzumab. From a HCP perspective, 
the total preparation and administration time for IV trastu-
zumab was 4.07 times longer than the total time required for 
SC administration. Also, IV administration was more costly, 
mainly due to more HCP time, more consumable supplies 
and drug wastage [20].
The BELIS study is to our knowledge the first prospec-
tive study evaluating the safety and patient experience of 
trastuzumab SC administered by a HCP at the home of the 
patient. During treatment in the hospital or at home, the 
observed safety profile of trastuzumab SC was consistent 
with the known safety profile of trastuzumab. As expected, 
more administration site reactions of mild intensity were 
reported with the SC administration. All patients agreed that 
they had benefit from at home administration to a large or 
very large extent. The SC administration is considered by 
the HCPs as the quickest way to administer trastuzumab. 
The results of the BELIS study support that trastuzumab SC 
can be safely and comfortably administered by a HCP at the 
home of the patient and this setting is beneficial for HER2, 
eBC patients undergoing treatment.
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